The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Open accessAbstract
Background: The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly. It is nowadays recognized as the most frequent liver disease, affecting a quarter of global population and regularly coexisting with metabolic disorders such as type 2 diabetes, hypertension, obesity, and cardiovascular disease. In a more simplistic view, NAFLD could be defined as an increase in liver fat content, in the absence of secondary cause of steatosis. In fact, the clinical onset of the disease is a much more complex process, closely related to insulin resistance, limited expandability and dysfunctionality of adipose tissue. A fatty liver is a main driver for a new recognized liver-pancreatic α-cell axis and increased glucagon, contributing to diabetes pathophysiology. Main text: This review will focus on the clinical and pathophysiological connections between NAFLD, insulin resistance and type 2 diabetes. We reviewed non-invasive methods and several scoring systems for estimative of steatosis and fibrosis, proposing a multistep process for NAFLD evaluation. We will also discuss treatment options with a more comprehensive view, focusing on the current available therapies for obesity and/or type 2 diabetes that impact each stage of NAFLD. Conclusion: The proper understanding of NAFLD spectrum—as a continuum from obesity to metabolic syndrome and diabetes—may contribute to the early identification and for establishment of targeted treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961 · cited 1×
“It has 2 mains definitions (Table 2) and is highly prevalent worldwide [16, 17].”
BackgroundDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Despite the limitations of liver biopsy, we highlight it is the gold-standard method for NASH and fibrosis evaluation, and may be considered in selected cases, such as suspicion of other liver disease [56, 57].”
MethodYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 4×
“Epidemiology Although epidemiological data involving more than 8 million people estimated a global prevalence of NAFLD around 25% [2], it certainly varies greatly depending on how it is diagnosed and on the region of the world considered.”
BackgroundInfluentialThe metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 12×
“Patients with obesity and/or MetS, with or without T2D, might be targeted promptly for ruling out NAFL/ NASH and fibrosis [3, 5, 6].”
BackgroundInfluentialEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 2×
“Genetic predisposition Genome-wide association (GWA) studies found several genetic variants associated with NAFLD, which implies in variability on individual susceptibility to the disease [39].”
Background
Research works printed but not linked: 1
- Stein DT, Szczepaniak L, Garg A, Malloy C, McGarry JD. Intramuscular lipid is increased in subjects with congenital generalized lipodystrophy (Abstract). Diabetes. 1997;46(Suppl. 1):242A.
Cited by
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Lim, G. E. H., Tang, A., Ng, C. H., Chin, Y. H., Lim, W. H., Tan, D. J. H., Yong, J. N., Xiao, J., Lee, C. W.-M., Chan, M., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.038 · Cited by 246
Liver biopsy for assessment of chronic liver diseases: a synopsis
Chowdhury, A. B., & Mehta, K. J. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00799-z · Cited by 225
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
Marušić, M., Paić, M., Knobloch, M., & Liberati Pršo, A.-M. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6613827 · Cited by 230
Vancells Lujan, P., Viñas Esmel, E., & Sacanella Meseguer, E. (2021) · Nutrients · doi:10.3390/nu13051442 · Cited by 209
“As mentioned before, its incidence is growing worldwide in parallel with overweight, obesity, T2DM, and MetS [5,13,16].”
BackgroundInfluential
Metadata
- Authors
- Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2020-07-14
- Volume
- 12
- Issue
- 1
- Pages
- 60-60
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC7359287
- OpenAlex
- W3043179056
- Cited by
- 643
- References
- 175
- Citations by year
- 2026: 56 · 2025: 111 · 2024: 148 · 2023: 142 · 2022: 109 · 2021: 72 · 2020: 4
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, obesity, metabolic syndrome, type 2 diabetes, insulin resistance, hepatic steatosis, liver fibrosis, adipose tissue dysfunction, glucagon, NAFLD treatment, disease continuum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. https://app.cochat.ai/papers/10.1186/s13098-020-00570-y
- The paper
- Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020). NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-020-00570-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.